Clinical Trial: The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07247656) titled 'The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .' on Sept. 17.

Brief Summary: The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study period of 12 weeks and individual study period of 4 weeks .

Study Start Date: Dec. 01, 2022

Study Type: INTERVENTIONAL

Condition: Diabete Mellitus

Intervention: DRUG: (Empagliflozin 10 mg+ Tab Linagliptin 5mg)

(Empagliflozin...